# Treatment Resistance Research TNBC can become hard to treat when it adapts to chemotherapy. Resistance often involves more than one shift at once. **EMT**, cancer stem-cell behaviour, drug efflux, mitochondrial rewiring, and survival signalling can all move together. This page is now the guide to the TNBC resistance section. The detailed write-ups live on the child pages below. ### In this section * [Why chemo-resistance is such a big issue in TNBC](#why-chemo-resistance-is-such-a-big-issue-in-tnbc) * [How to use these pages](#how-to-use-these-pages) * [What this does and does not mean in practice](#what-this-does-and-does-not-mean-in-practice) * [TNBC Natural Compounds in Treatment Resistance Research](/myhealingcommunity-docs/breast-cancer/triple-negative/treatment-resistance-research/tnbc-natural-compounds-in-treatment-resistance-research.md) * [TNBC Off-Label Drugs in Treatment Resistance Research](/myhealingcommunity-docs/breast-cancer/triple-negative/treatment-resistance-research/tnbc-off-label-drugs-in-treatment-resistance-research.md) * [Emerging Resistance Strategies](/myhealingcommunity-docs/breast-cancer/triple-negative/treatment-resistance-research/emerging-resistance-strategies.md) {% hint style="warning" %} This section mainly tracks **preclinical research**. The **Emerging Resistance Strategies** page also includes a small number of early clinical combination signals because they show where resistance-directed treatment may be heading. Do not add **piperlongumine**, **pterostilbene**, **pitavastatin**, or other agents on the basis of this section without oncology and pharmacy review. {% endhint %} ### Why chemo-resistance is such a big issue in TNBC TNBC often behaves more aggressively than receptor-positive disease. It also has fewer standard targeted options. That makes treatment escape more consequential. Common resistance themes include: * **EMT** and invasion * cancer stem-cell persistence * **P-glycoprotein** and other efflux pumps * **AKT/STAT3** and related survival pathways * mitochondrial adaptation and apoptosis evasion These themes help explain why natural compounds and repurposed drugs keep drawing attention. Researchers are looking for agents that hit several of them at once. ### Key pages in this section The constantly updated treatment resistance research is divided into sub-sections. #### Natural compounds [TNBC Natural Compounds in Treatment Resistance Research](/myhealingcommunity-docs/breast-cancer/triple-negative/treatment-resistance-research/tnbc-natural-compounds-in-treatment-resistance-research.md) already covers **pterostilbene**, blueberry findings, **piperlongumine**, and the microRNA logic linking them to resistance research. #### Off-label drugs [TNBC Off-Label Drugs in Treatment Resistance Research](/myhealingcommunity-docs/breast-cancer/triple-negative/treatment-resistance-research/tnbc-off-label-drugs-in-treatment-resistance-research.md) covers work on repurposed-drug leads such as **pitavastatin**, **melatonin**, and **metformin**. #### Emerging strategies [Emerging Resistance Strategies](/myhealingcommunity-docs/breast-cancer/triple-negative/treatment-resistance-research/emerging-resistance-strategies.md) covers RNA-level targeting and next-wave combination approaches. ### How to use these pages 1. Start with the page that matches the type of idea you are checking. 2. Use the interaction and safety cautions to screen out weak self-directed add-ons. 3. Bring any shortlist to oncology and pharmacy review before acting on it. ### What this does and does not mean in practice Most of the strategies in this section are still not proven clinical ways to prevent or reverse TNBC resistance. The most useful takeaways are: * natural compounds such as **pterostilbene**, blueberries, and **piperlongumine** are still preclinical leads * **pitavastatin** is an especially interesting repurposing lead, but not yet a validated TNBC treatment * some **multi-target combinations** are now generating real human efficacy data, but they are regimen-specific oncology treatments, not self-directed add-ons * resistance biology is becoming more targetable as researchers focus on **EMT**, stem-cell programs, efflux, apoptosis escape, and immune evasion together Any addition during active treatment needs oncology and pharmacy review first. That is especially true for concentrated supplements, off-label drugs, or multi-agent stacks. {% hint style="info" %} ### In this TNBC resistance series * [Treatment Resistance Research](/myhealingcommunity-docs/breast-cancer/triple-negative/treatment-resistance-research.md) * [TNBC Natural Compounds in Treatment Resistance Research](/myhealingcommunity-docs/breast-cancer/triple-negative/treatment-resistance-research/tnbc-natural-compounds-in-treatment-resistance-research.md) * [TNBC Off-Label Drugs in Treatment Resistance Research](/myhealingcommunity-docs/breast-cancer/triple-negative/treatment-resistance-research/tnbc-off-label-drugs-in-treatment-resistance-research.md) * [Emerging Resistance Strategies](/myhealingcommunity-docs/breast-cancer/triple-negative/treatment-resistance-research/emerging-resistance-strategies.md) {% endhint %} {% hint style="warning" %} This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use. {% endhint %} {% hint style="info" %} © 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text. {% endhint %} --- # Agent Instructions: Querying This Documentation If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question. Perform an HTTP GET request on the current page URL with the `ask` query parameter: ``` GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/breast-cancer/triple-negative/treatment-resistance-research.md?ask= ``` The question should be specific, self-contained, and written in natural language. The response will contain a direct answer to the question and relevant excerpts and sources from the documentation. Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.